# Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts Canonical URL: https://biopharmsignal.com/news/ACRV/acrivon-reports-first-quarter-2026-financial-results-and-highlights-progress-towards-key-2026-clinical-catalysts Ticker: ACRV Company: Acrivon Therapeutics Source: Acrivon Therapeutics Published: 2026-05-13 20:10 EST Original Source URL: https://ir.acrivon.com ## Summary The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026  The ACR-2316 Phase 1/2 study is advancing towards expansion phase demonstrating ## Article Body The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026 The ACR-2316 Phase 1/2 study is advancing towards expansion phase demonstrating ## Recent Company News - 2026-05-21 11:30 EST — [Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-present-at-td-cowen-s-7th-annual-oncology-innovation-summit) — Source: Acrivon Therapeutics - 2026-05-13 20:10 EST — [Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts](https://biopharmsignal.com/news/ACRV/acrivon-reports-first-quarter-2026-financial-results-and-highlights-progress-towards-key-2026-clinical-catalysts) — Source: Acrivon Therapeutics - 2026-04-17 20:00 EST — [Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities](https://biopharmsignal.com/news/ACRV/acrivon-to-highlight-preclinical-data-with-three-posters-at-aacr-demonstrating-strong-acr-368-and-acr-2316-synergies-with-immune-checkpoint-inhibitors-and-adc-payloads-revealing-broad-clinical-development-opportunities) — Source: Acrivon Therapeutics - 2026-04-15 20:05 EST — [Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Acrivon Therapeutics - 2026-03-19 11:21 EST — [Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights) — Source: Acrivon Therapeutics ## Related News - 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8) - 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05) - 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004) - 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7) - 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)